Bio-Techne (TECH) Proxy filing summary

Executive summary

• Merger agreement signed for acquisition by Merck KGaA, Darmstadt, Germany, with closing expected by late 2026 or early 2027, pending regulatory and shareholder approvals.

• Both companies will operate independently until closing, with a focus on business continuity and compliance with legal requirements.

• Integration aims to leverage complementary strengths, retain critical talent, and expand global reach and capabilities.

• Forward-looking statements highlight risks such as integration challenges, regulatory approvals, and potential business disruptions.

Voting matters and shareholder proposals

• Shareholder approval is required for the transaction to proceed.

• Proxy materials will be filed with the SEC and made available to shareholders for voting.

Board of directors and corporate governance

• Information about directors and executive officers, including compensation and governance, is referenced in prior proxy statements and SEC filings.

• Any changes in holdings by directors or officers will be disclosed in future SEC filings.